GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Sunshine Lake Pharma Co 6887.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

38.82

+0.05%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥4.82bn

FY2022FY2025

Net income

CN¥272.4m

FY2022FY2025

Free cash flow

CN¥228.3m

FY2022FY2025

Shareholders' equity

CN¥4.34bn

FY2022FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022
RevenueCN¥4.82bnCN¥4.02bnCN¥6.39bnCN¥3.81bn
Gross profitCN¥3.69bnCN¥3.06bnCN¥5.08bnCN¥2.92bn
Research and developmentCN¥648.7mCN¥887.7mCN¥827.4mCN¥791.6m
Operating incomeCN¥631.1mCN¥380.5mCN¥1.77bn−CN¥792.9m
Net incomeCN¥272.4m−CN¥207.4mCN¥184.9m−CN¥1.21bn
Diluted earnings per share0.47-0.360.32-2.10

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022
Total assetsCN¥11.99bnCN¥11.93bnCN¥12.66bnCN¥10.69bn
Cash and short-term investments—CN¥1.48bnCN¥1.92bnCN¥1.26bn
Total liabilitiesCN¥7.65bnCN¥11.59bnCN¥12.33bnCN¥14.38bn
DebtCN¥1.28bnCN¥2.39bnCN¥2.03bnCN¥7.64bn
Shareholders' equityCN¥4.34bnCN¥344.1mCN¥327.9m−CN¥3.69bn
Shares outstanding576m577m576m576m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022
Cash from operationsCN¥1.16bnCN¥500.5mCN¥1.32bnCN¥1.16bn
Capital spending−CN¥926.9m−CN¥1.23bn−CN¥535.2m−CN¥1.02bn
Free cash flowCN¥228.3m−CN¥724.7mCN¥782.9mCN¥143.7m
Dividends paid−CN¥584.4m———

Latest quarters

By quarter end

Jun 2025Dec 2024Jun 2024
RevenueCN¥1.94bnCN¥1.44bnCN¥2.58bn
Gross profitCN¥1.47bnCN¥1.02bnCN¥2.04bn
Operating incomeCN¥209.9m−CN¥357.0mCN¥737.5m
Net income−CN¥46.4m−CN¥349.6mCN¥142.1m
Diluted earnings per share-0.08-0.610.25
Cash from operationsCN¥20.0mCN¥500.0mCN¥83.0m
Capital spending−CN¥773.0m−CN¥1.23bn−CN¥612.0m
Free cash flow−CN¥753.0m−CN¥725.0m−CN¥529.0m
Total assetsCN¥12.06bnCN¥11.93bn—
Cash and short-term investmentsCN¥1.07bn——
DebtCN¥2.25bnCN¥2.09bn—
Shareholders' equityCN¥391.2mCN¥344.1m—

Financial ratios

Data as of 25 Sept 2026

FY2025FY2024FY2023FY2022
Gross margin76.5%76.1%79.5%76.6%
Operating margin13.1%9.5%27.7%-20.8%
Net margin5.7%-5.2%2.9%-31.7%
Return on equity6.3%-60.3%56.4%32.8%
Return on assets2.3%-1.7%1.5%-11.3%
Free cash flow yield9.1%7.6%——
Revenue growth19.8%-37.1%67.4%—
Earnings growth-231.3%-212.2%-115.3%—
Current ratio0.77x1.03x1.04x0.46x
Debt to equity0.29x6.65x5.98x-2.05x
Equity ratio36.2%2.9%2.6%-34.5%
Interest coverage2.74x5.27x2763.82x-0.73x
R&D as a share of sales13.5%22.1%13.0%20.8%
Buybacks as a share of market value0.1%———

Growth per year

Compound annual rate

3 years5 years10 years
Revenue22.5%——

Average margins

Over each period

1 year3 years5 years10 years
Gross margin76.3%77.5%——

Valuation history

At each fiscal year end

FY2025
Price to earnings86.7
Price to sales5.2

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.